Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -30.03% is 33% above its 5-year average of -44.80%, near the high end of its 5-year range (-214.71%–-18.06%).
As of the fiscal period ended Tuesday, June 30, 2026. 53.68% above its 12-month average of -64.83%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -30.03%.
RETURN ON EQUITY (ROE)
-30.03%
RETURN ON EQUITY (ROE) AVG TTM
-64.83%
RETURN ON EQUITY (ROE) AVG 3Y
-67.69%
RETURN ON EQUITY (ROE) AVG 5Y
-44.80%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+53.68%
CURRENT VS 3Y AVG
+55.64%
CURRENT VS 5Y AVG
+32.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.54%
median of 549 covered companies
CURRENT VS SECTOR MEDIAN
+24.05%
vs the sector median at left
Immuneering Corporation
Market Cap
$144.48M
Return on Equity (ROE)
-30.03%
TTM Avg
-64.83%
3Y Avg
-67.69%
5Y Avg
-44.80%
Market Cap
$142.60M
Return on Equity (ROE)
-120.33%
TTM Avg
-117.87%
3Y Avg
-76.44%
5Y Avg
-55.77%
Market Cap
$144.00M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$147.13M
Return on Equity (ROE)
-397.38%
TTM Avg
-1100.28%
3Y Avg
-310.11%
5Y Avg
-250.84%
Market Cap
$140.03M
Return on Equity (ROE)
-11.20%
TTM Avg
-11.86%
3Y Avg
-12.45%
5Y Avg
-5.17%
Market Cap
$150.23M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$147.97M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$139.63M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$139.73M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $144.48M | -30.03% | -64.83% | -67.69% | -44.80% |
| Nyxoah S.A. (NYXH)vs › | $142.60M | -120.33% | -117.87% | -76.44% | -55.77% |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.00M | -131.85% | -36.69% | -135.43% | -129.92% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.13M | -397.38% | -1100.28% | -310.11% | -250.84% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $140.03M | -11.20% | -11.86% | -12.45% | -5.17% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.23M | -183.44% | -114.28% | -67.72% | -46.03% |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -266.86% | 156.76% | 98.17% | -694.29% |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | -44.26% | -34.18% | 285.39% | -5868.11% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 68.12% | -94.32% | -166.28% | -128.51% |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.65M | -10.08% | -25.77% | -36.68% | -27.09% |
ROE
-30.0%
ROA
-28.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -30.03% |
| 2026-03-31 | -26.36% |
| 2025-12-31 | -25.64% |
| 2025-09-30 | -27.41% |
| 2025-06-30 | -214.71% |
| 2025-03-31 | -147.64% |
| 2024-12-31 | -147.48% |
| 2024-09-30 | -100.60% |
| 2024-06-30 | -84.56% |
| 2024-03-31 | -68.82% |
| 2023-12-31 | -59.03% |
| 2023-09-30 | -49.64% |
| 2023-06-30 | -45.07% |
| 2023-03-31 | -52.38% |
| 2022-12-31 | -45.98% |
| 2022-09-30 | -39.42% |
| 2022-06-30 | -32.74% |
| 2022-03-31 | -27.91% |
| 2021-12-31 | -21.50% |
| 2021-09-30 | -18.06% |
| 2021-06-30 | -51.26% |
| 2021-03-31 | -67.86% |
